"PTEN Phosphohydrolase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lipid phosphatase that contains a C2 DOMAIN and acts on phosphatidylinositol-3,4,5-trisphosphate to regulate various SIGNAL TRANSDUCTION PATHWAYS. It modulates CELL GROWTH PROCESSES; CELL MIGRATION; and APOPTOSIS. Mutations in PTEN are associated with COWDEN DISEASE and PROTEUS SYNDROME as well as NEOPLASTIC CELL TRANSFORMATION.
| Descriptor ID |
D051059
|
| MeSH Number(s) |
D08.811.277.352.650.850 D12.776.476.590 D12.776.624.776.695
|
| Concept/Terms |
PTEN Phosphohydrolase- PTEN Phosphohydrolase
- Phosphohydrolase, PTEN
- PTEN Protein
- Phosphatase and Tensin Homologue on Chromosome Ten Protein
- PTEN Phosphatase
- Phosphatase, PTEN
- MMAC1 Protein
- PTEN Protein Phosphatase
- Phosphatase, PTEN Protein
- Protein Phosphatase, PTEN
- Mutated In Multiple Advanced Cancers 1 Protein
|
Below are MeSH descriptors whose meaning is more general than "PTEN Phosphohydrolase".
Below are MeSH descriptors whose meaning is more specific than "PTEN Phosphohydrolase".
This graph shows the total number of publications written about "PTEN Phosphohydrolase" by people in this website by year, and whether "PTEN Phosphohydrolase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 10 | 10 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 9 | 9 |
| 2002 | 0 | 13 | 13 |
| 2003 | 1 | 10 | 11 |
| 2004 | 0 | 7 | 7 |
| 2005 | 4 | 13 | 17 |
| 2006 | 11 | 10 | 21 |
| 2007 | 10 | 8 | 18 |
| 2008 | 15 | 6 | 21 |
| 2009 | 16 | 9 | 25 |
| 2010 | 15 | 5 | 20 |
| 2011 | 16 | 16 | 32 |
| 2012 | 15 | 18 | 33 |
| 2013 | 12 | 13 | 25 |
| 2014 | 11 | 13 | 24 |
| 2015 | 25 | 8 | 33 |
| 2016 | 10 | 10 | 20 |
| 2017 | 18 | 11 | 29 |
| 2018 | 9 | 5 | 14 |
| 2019 | 11 | 3 | 14 |
| 2020 | 5 | 5 | 10 |
| 2021 | 3 | 5 | 8 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 4 | 5 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "PTEN Phosphohydrolase" by people in Profiles.
-
Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies. Blood Adv. 2024 10 22; 8(20):5279-5289.
-
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024 Oct; 189:138-145.
-
Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotype. Genes Dev. 2024 04 17; 38(5-6):273-288.
-
eEF1A2 promotes PTEN-GSK3?-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Sci Signal. 2024 03 05; 17(826):eadh4475.
-
Spinster homolog 2 reduces malignancies of glioblastoma via PTEN/PI3K/AKT pathway. IUBMB Life. 2024 Mar; 76(3):140-160.
-
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer. Nat Commun. 2023 09 13; 14(1):5665.
-
The Rare and Atypical Diabetes Network (RADIANT) Study: Design and Early Results. Diabetes Care. 2023 06 01; 46(6):1265-1270.
-
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors. Cancer. 2023 06 15; 129(12):1919-1929.
-
Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma. J Invest Dermatol. 2023 09; 143(9):1779-1787.e1.
-
Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss. Cell Death Dis. 2022 09 08; 13(9):777.